U.S. Markets open in 7 hrs 20 mins

Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences

NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Aralez Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARZ.TO

OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

Aralez Pharmaceuticals' stock had no change Friday, to close the day at $0.43. The stock recorded a trading volume of 274,400 shares, which was above its three months average volume of 71,219 shares. In the last year, Aralez Pharmaceuticals' shares have traded in a range of 0.29 - 3.72. The share price has gained 48.28% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.42 is below its 200-day moving average of $1.06. Shares of Aralez Pharmaceuticals have fallen approximately 75.98 percent year-to-date.

Access RDI's Aralez Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARZ.TO

On Friday, shares of OrganiGram Holdings recorded a trading volume of 4,726,039 shares, which was above the three months average volume of 964,282 shares. The stock ended the day 1.48% higher at 6.85. The share price has gained 212.79% from its 52 week low with a 52 week trading range of 2.19 - 7.46. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.42 is greater than its 200-day moving average of $4.77. Shares of OrganiGram Holdings are trading at a Price to Earnings ratio of 2,283.33. Shares of OrganiGram Holdings have gained approximately 67.07 percent year-to-date.

Access RDI's OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech's stock jumped 10.91% Friday, to close the day at $6.00. The stock recorded a trading volume of 54,165 shares, which was above its three months average volume of 17,425 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 5.00 - 10.67. The share price has gained 20.00% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $5.89 is below its 200-day moving average of $7.02. Shares of Oncolytics Biotech have fallen approximately 11.27 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Friday, shares of Aptose Biosciences recorded a trading volume of 25,296 shares, which was below the three months average volume of 42,522 shares. The stock ended the day 1.50% higher at 4.05. The share price has gained 146.95% from its 52 week low with a 52 week trading range of 1.64 - 5.97. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.80 is below its 200-day moving average of $4.31. Shares of Aptose Biosciences have gained approximately 45.68 percent year-to-date.

Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

Our Actionable Research on Aralez Pharmaceuticals Inc. (TSX:ARZ.TO), OrganiGram Holdings Inc. (TSXV:OGI.V), Oncolytics Biotech Inc. (TSX:ONC.TO) and Aptose Biosciences Inc. (TSX:APS.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

https://www.accesswire.com/511632/Todays-Research-Reports-on-Aralez-Pharmaceuticals-OrganiGram-Holdings-Oncolytics-Biotech-and-Aptose-Biosciences